Virtus Fund Advisers LLC purchased a new stake in Aduro BioTech Inc (NASDAQ:ADRO) during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor purchased 42,735 shares of the biotechnology company’s stock, valued at approximately $321,000.
A number of other institutional investors also recently added to or reduced their stakes in the business. Wilbanks Smith & Thomas Asset Management LLC bought a new position in Aduro BioTech in the 4th quarter valued at about $191,000. Alps Advisors Inc. raised its holdings in Aduro BioTech by 12.5% in the 4th quarter. Alps Advisors Inc. now owns 82,678 shares of the biotechnology company’s stock valued at $620,000 after acquiring an additional 9,197 shares during the period. Fox Run Management L.L.C. raised its holdings in Aduro BioTech by 91.4% in the 4th quarter. Fox Run Management L.L.C. now owns 22,775 shares of the biotechnology company’s stock valued at $171,000 after acquiring an additional 10,875 shares during the period. Nisa Investment Advisors LLC raised its holdings in Aduro BioTech by 2,294.1% in the 4th quarter. Nisa Investment Advisors LLC now owns 24,420 shares of the biotechnology company’s stock valued at $183,000 after acquiring an additional 23,400 shares during the period. Finally, Point72 Asset Management L.P. bought a new position in Aduro BioTech in the 3rd quarter valued at about $1,023,000. 42.61% of the stock is currently owned by hedge funds and other institutional investors.
Aduro BioTech Inc (ADRO) opened at $6.60 on Monday. Aduro BioTech Inc has a fifty-two week low of $5.82 and a fifty-two week high of $14.05. The company has a market cap of $510.20 and a P/E ratio of -4.85.
In related news, insider Stephen T. Isaacs sold 40,000 shares of the stock in a transaction that occurred on Friday, December 1st. The shares were sold at an average price of $9.38, for a total transaction of $375,200.00. Following the sale, the insider now owns 213,921 shares in the company, valued at approximately $2,006,578.98. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, COO Gregory W. Schafer sold 20,000 shares of the stock in a transaction that occurred on Tuesday, January 2nd. The stock was sold at an average price of $7.61, for a total transaction of $152,200.00. Following the sale, the chief operating officer now owns 190,745 shares in the company, valued at approximately $1,451,569.45. The disclosure for this sale can be found here. Insiders have sold 172,656 shares of company stock worth $1,486,582 over the last ninety days. Insiders own 6.60% of the company’s stock.
About Aduro BioTech
Aduro Biotech, Inc is an immunotherapy company, which focuses on the discovery, development and commercialization of therapies that manage the treatment of various diseases, including cancer. The Company’s product candidates from its Live, Attenuated, Double-Deleted (LADD) Listeria monocytogenes, Stimulator of Interferon Genes Pathway Activator, and B-select monoclonal antibody platforms are designed to stimulate and/or regulate innate and adaptive immune responses, either as single agents or in combination with conventional therapies, as well as other immunotherapies.
Want to see what other hedge funds are holding ADRO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Aduro BioTech Inc (NASDAQ:ADRO).
Receive News & Ratings for Aduro BioTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aduro BioTech and related companies with MarketBeat.com's FREE daily email newsletter.